123 related articles for article (PubMed ID: 31177178)
1.
Chaszczewska-Markowska M; Kosacka M; Chryplewicz A; Dyła T; Brzecka A; Bogunia-Kubik K
Anticancer Res; 2019 Jun; 39(6):3269-3272. PubMed ID: 31177178
[TBL] [Abstract][Full Text] [Related]
2. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
3. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
Gao H; Ge RC; Liu HY; Wang Y; Yan S
Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
[TBL] [Abstract][Full Text] [Related]
4. Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis.
Zhu J; Hua RX; Jiang J; Zhao LQ; Sun X; Luan J; Lang Y; Sun Y; Shang K; Peng S; Ma J
PLoS One; 2014; 9(5):e97616. PubMed ID: 24841208
[TBL] [Abstract][Full Text] [Related]
5. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
Zhao X; Zhang Z; Yuan Y; Yuan X
Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
[TBL] [Abstract][Full Text] [Related]
7. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression.
Yu T; Xue P; Cui S; Zhang L; Zhang G; Xiao M; Zheng X; Zhang Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Cancer Med; 2018 Dec; 7(12):6317-6330. PubMed ID: 30453383
[TBL] [Abstract][Full Text] [Related]
8. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
11. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.
Koç E; Caner V; Büyükpınarbaşılı N; Tepeli E; Türk NS; Ozan Çetin G; Bağcı G
Mol Biol Rep; 2012 Jan; 39(1):375-80. PubMed ID: 21553053
[TBL] [Abstract][Full Text] [Related]
12. NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival.
Dimitrakopoulos FD; Antonacopoulou AG; Kottorou AE; Maroussi S; Panagopoulos N; Koukourikou I; Scopa C; Kalofonou M; Koutras A; Makatsoris T; Papadaki H; Dougenis D; Brock M; Kalofonos HP
Sci Rep; 2018 Mar; 8(1):5259. PubMed ID: 29588475
[TBL] [Abstract][Full Text] [Related]
13. Association of excision repair cross-complimentary group 1 gene polymorphisms with breast and ovarian cancer susceptibility.
Yang F; Mu X; Bian C; Zhang H; Yi T; Zhao X; Lin X
J Cell Biochem; 2019 Sep; 120(9):15635-15647. PubMed ID: 31081240
[TBL] [Abstract][Full Text] [Related]
14. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
Bao Y; Yang B; Zhao J; Shen S; Gao J
Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
16. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.
Zhao Z; Zhang A; Zhao Y; Xiang J; Yu D; Liang Z; Xu C; Zhang Q; Li J; Duan P
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29669843
[TBL] [Abstract][Full Text] [Related]
17. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
18. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.
Qian B; Zhang H; Zhang L; Zhou X; Yu H; Chen K
Lung Cancer; 2011 Aug; 73(2):138-46. PubMed ID: 21195504
[TBL] [Abstract][Full Text] [Related]
19. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA.
Lu B; Li J; Gao Q; Yu W; Yang Q; Li X
Gene; 2014 May; 542(1):64-8. PubMed ID: 24582975
[TBL] [Abstract][Full Text] [Related]
20. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
